TWI924683B - 三苯基鈣敏感性化合物之調配物 - Google Patents

三苯基鈣敏感性化合物之調配物

Info

Publication number
TWI924683B
TWI924683B TW110128669A TW110128669A TWI924683B TW I924683 B TWI924683 B TW I924683B TW 110128669 A TW110128669 A TW 110128669A TW 110128669 A TW110128669 A TW 110128669A TW I924683 B TWI924683 B TW I924683B
Authority
TW
Taiwan
Prior art keywords
weight
tablet formulation
amount
compound
tablet
Prior art date
Application number
TW110128669A
Other languages
English (en)
Chinese (zh)
Other versions
TW202220642A (zh
Inventor
烏瑪 辛哈
阿南特 斯里達
莉娜 普拉薩德
阿里 柯梅力
Original Assignee
美商柯西立提克斯療法有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商柯西立提克斯療法有限公司 filed Critical 美商柯西立提克斯療法有限公司
Publication of TW202220642A publication Critical patent/TW202220642A/zh
Application granted granted Critical
Publication of TWI924683B publication Critical patent/TWI924683B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW110128669A 2020-08-04 2021-08-04 三苯基鈣敏感性化合物之調配物 TWI924683B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063061050P 2020-08-04 2020-08-04
US63/061,050 2020-08-04

Publications (2)

Publication Number Publication Date
TW202220642A TW202220642A (zh) 2022-06-01
TWI924683B true TWI924683B (zh) 2026-05-11

Family

ID=77431430

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110128669A TWI924683B (zh) 2020-08-04 2021-08-04 三苯基鈣敏感性化合物之調配物

Country Status (13)

Country Link
US (2) US20220040112A1 (enExample)
EP (1) EP4192438A1 (enExample)
JP (2) JP7827696B2 (enExample)
KR (1) KR20230106582A (enExample)
CN (1) CN116648243A (enExample)
AR (1) AR123147A1 (enExample)
AU (1) AU2021320147B2 (enExample)
BR (1) BR112023002107A2 (enExample)
CA (1) CA3188044A1 (enExample)
IL (1) IL300285A (enExample)
MX (1) MX2023001438A (enExample)
TW (1) TWI924683B (enExample)
WO (1) WO2022031666A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116648243A (zh) 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂
MX2023003129A (es) * 2020-09-18 2023-08-04 Calcilytix Therapeutics Inc Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1).
WO2024160842A1 (en) 2023-01-30 2024-08-08 Medizinische Universität Wien Use of calcilytics for preventing or treating hypoparathyroidism associated with anterior neck surgery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1741984A (zh) * 2003-04-23 2006-03-01 日本烟草产业株式会社 CaSR拮抗剂
CN102365261A (zh) * 2009-03-26 2012-02-29 日本烟草产业株式会社 制备羧酸化合物的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1964548A1 (en) * 2007-03-02 2008-09-03 Novartis AG Pharmaceutical compositions comprising a calcilytic agent
ES2900353T3 (es) * 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
GB201217330D0 (en) * 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
BR112020013073A2 (pt) 2017-12-29 2020-12-01 Biomarin Pharmaceutical Inc. composto, composto, estereoisômero único ou mistura de estereoisômeros ou sal farmaceuticamente aceitável, composição farmacêutica, método de tratamento de uma doença ou distúrbio e composto ou sal farmaceuticamente aceitável do mesmo
WO2021029517A1 (en) 2019-08-13 2021-02-18 Dongguk University Industry-Academic Cooperation Foundation Pharmaceutical composition for improving or treating post-surgical hypoparathyroidism and treatment method using the same
GB201918586D0 (en) * 2019-12-17 2020-01-29 Patterson James Engineered platelets for targeted delivery of a therapeutic agent
CN116648243A (zh) 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂
MX2023003129A (es) 2020-09-18 2023-08-04 Calcilytix Therapeutics Inc Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1).

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1741984A (zh) * 2003-04-23 2006-03-01 日本烟草产业株式会社 CaSR拮抗剂
CN102365261A (zh) * 2009-03-26 2012-02-29 日本烟草产业株式会社 制备羧酸化合物的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Antoine Al-Achi "Tablets: A Brief Overview." J Pharm Pract Pharm Sci 03 June, 2019 (1): 50-53 *

Also Published As

Publication number Publication date
BR112023002107A2 (pt) 2023-03-07
CN116648243A (zh) 2023-08-25
AR123147A1 (es) 2022-11-02
US12357576B2 (en) 2025-07-15
EP4192438A1 (en) 2023-06-14
MX2023001438A (es) 2023-06-15
JP7827696B2 (ja) 2026-03-10
TW202220642A (zh) 2022-06-01
AU2021320147B2 (en) 2026-07-30
US20220040112A1 (en) 2022-02-10
CA3188044A1 (en) 2022-02-10
JP2026086851A (ja) 2026-05-26
KR20230106582A (ko) 2023-07-13
IL300285A (en) 2023-04-01
JP2023536667A (ja) 2023-08-28
WO2022031666A1 (en) 2022-02-10
US20240074978A1 (en) 2024-03-07
AU2021320147A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
EP3641742B1 (en) Hydroxynorketamine for the use in the treatment of depression
DE60221691T3 (de) Tamsulosin tabletten ohne nahrungsmitteleffekt
US12357576B2 (en) Formulations of triphenyl calcilytic compounds
JP5763063B2 (ja) イルベサルタンおよびアムロジピンを含む固体医薬固定用量組成物、これらの調製ならびにこれらの治療用途
EP2568806B1 (en) Therapeutic regimens
PL220457B1 (pl) Kapsułka do leczenia dysurii
US20230293495A1 (en) Pharmaceutical formulations for treating diseases mediated by kdm1a
US20210401860A1 (en) Pharmaceutical formulations comprising 5-Chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine
US9572806B2 (en) Elution-stabilized preparation
US12251475B2 (en) Solid pharmaceutical formulations of asimadoline
US20240100011A1 (en) Pediatric formulations of ferric citrate
US20240100088A1 (en) Novel formulation for treating copper metabolism-associated diseases or disorders
CN113347975A (zh) 用于治疗侵蚀性手骨关节炎的孟鲁司特
US8309607B2 (en) Rapid release irbesartan-containing pharmaceutical composition
EP4081210B1 (en) Pharmaceutical composition of casr modulators and methods and uses thereof
US20250288540A1 (en) Methods and compositions for pain management
WO2026088136A1 (en) Methods of treating a neurodegenerative disease
RU2773029C2 (ru) Галеновые композиции органических соединений
JP5946135B2 (ja) トリクロルメチアジドおよび結晶セルロースを含有する固形製剤
HK40101454B (en) Tablet for use in treating huntington's disease and method of making the same
HK40101454A (en) Tablet for use in treating huntington's disease and method of making the same
JP2022536955A (ja) ジクロフェナミド組成物及び使用方法
EA012845B1 (ru) Фармацевтическая композиция, содержащая зофеноприл и hctz, для лечения гипертензии